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PurDose, Vascular endothelial growth factor (VEGF) 
stimulates retinal capillary endothelial cell proliferation 
through the activation of its receptor KDR. To investigate the 
role of VEGF in the onset of neovascularization we 
designed circulating agonists of KDR and looked at their 
angiogenic potential. - 
Method. Anti-VEGF idiotypic antibodies were elicited in 
rabbits and screened for their KDR specificity. 5 pg of anti 
idiotypic IgG were injected twice weekly intraperitoneously 
to rats who received slow-releasing implants containing 200 
ng of VEGF or the vehicule alone. 
Results. KDR ligands stimulate in vitro the phosphorylation 
of KDR on tyrosine residues and thme proliferation, but not the 
migration, of cultured vascular endothelial cells. In vivo KDR 
ligands promote angiogenesis in the cornea1 pocket assay. 
In addition systemic injections 01 KDR ligands induce an 
angiogenic response to pellet containing the vehicule alone 
and enhance that of VEGF. 
Conclusion. These results suggest that a local traumatism 
is sufficient to elicit the expresision of functional KDR 
receptors and that their activation triggers an angiogenic 
response even in the absence of VEGF. 
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avpPae Several compounds have been developed for the inhibition of 
neovascularizations. However experience with human use of such 
substances is limited since most of them have not been approved as 
drugs. In contrast suramin has been successfully used for tropical 
diseases in humans since several decades. We have investigated its 
effect on ocular neovascularizations in the cornea1 micropocket 
model. 
M&Q& Hydmn NCCXB served as slow release-pellet for 500 ng basic 
fibroblast growth factor (bFGF) into the stroma of rabbits following 
its implantation into a cornea1 micropocket. In control animals 
vessels originating from the limbus migrated towards the pellet and 
were quantified on day 3,6 and 9. Animals were treated with a single 
i.v. injection of suramin (150 mg/kg Gemxmi&) in conjunction with a 
single dose of 5 mg/kg prednisolone i.m. the day before surgery. 
&,u&& 10 eyes developed neovascularizations starting on day 3 
which roached the oellet at about dav 10 -14. Animals treated with 
Suramin did not SLOW any newly formed vessels but only a slight 
haze between polymer and the limbus. 
Conelusion Combined treatment with suramin and steroids can 
comdetelv m-event the mOwth of txxneal vessels in remonse to FGF. 
This effe&-might be due a antagonism against the growth factor 
bFGF and direct inhibition of the proliferation of vascular endothelial 
cells as well as inhibition of plasmin activator. Since suramin - in 
combination with steroids - completely inhibits any 
neovascularization an investigation of its effects on other forms of 
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